ArticlePloS one2022
The structural changes of gray matter in Parkinson disease patients with mild cognitive impairments.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Diffusion Magnetic Resonance Imaging of Cortical Microstructure Differs in Nonmanifest and Manifest Genetic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Associations between altered morphometric inverse divergence networks, choroid plexus volume, and perivascular space network in patients with Parkinson disease: a cross-sectional study.Quantitative imaging in medicine and surgery · 2026Article
- Structural covariance network alterations across the spectrum of cognitive status in Parkinson's disease.Clinical parkinsonism & related disorders · 2026Review
- Multi-modal machine learning approach for early detection of neurodegenerative diseases leveraging brain MRI and wearable sensor data.PLOS digital health · 2025Article
- Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Cognitive Impairment in Chronic Kidney Disease Across Different Stages: The Role of Structural and Perfusion-Driven Functional Connectivity Changes.Brain and behavior · 2025Article
- The role ofFrontiers in neuroscience · 2025Review
- Vitamin D-linked vulnerability and functional connectivity alterations in the superior frontal gyrus contributing to cognitive impairment in Parkinson's disease.Frontiers in aging neuroscience · 2025Article
- Review
- Analysis of cognitive dysfunction in Parkinson's disease using voxel based morphometry and radiomics.Cognitive processing · 2024Article
- Mapping brain morphology to cognitive deficits: a study on PD-CRS scores in Parkinson's disease with mild cognitive impairment.Frontiers in neuroanatomy · 2024Article
- Predicting the occurrence of mild cognitive impairment in Parkinson's disease using structural MRI data.Frontiers in neuroscience · 2024Article
- Diffusion and structural MRI as potential biomarkers in people with Parkinson's disease and cognitive impairment.European radiology · 2024Article
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- Article
- Mitochondrial DNA damage triggers spread of Parkinson's disease-like pathology.Molecular psychiatry · 2023Article
- Functional comorbidities and brain tissue changes before and after lung transplant in adults.Frontiers in cellular neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesParkinson disease (PD) is associated with cognitive impairments. However, the underlying neural mechanism of cognitive impairments in PD is still not clear. This study aimed to investigate the anatomic alternations of gray matter in PD patients with mild cognitive impairment (MCI) and their associations with neurocognitive measurements.
methodsT1-weighted magnetic resonance imaging (MRI) data were acquired from 23 PD patients with MCI, 23 PD patients without MCI, and 23 matched healthy controls. The MRI data were analyzed using voxel-based morphometry (VBM) and surfaced-based morphometry (SBM) methods to assess the structural changes in gray matter volume and cortical thickness respectively. Receiver operating characteristic (ROC) analysis was used to examine the diagnostic accuracies of the indexes of interest. The correlations between the structural metrics and neurocognitive assessments (e.g., Montreal cognitive assessment, MOCA; Mini-mental state examination, MMSE) were further examined.
resultsPD patients with MCI showed reduced gray matter volume (GMV) in the frontal cortex (e.g., right inferior frontal gyrus and middle frontal gyrus) and extended to insula as well as cerebellum compared with the healthy controls and PD patients without MIC. Thinner of cortical thickens in the temporal lobe (e.g., left middle temporal gyrus and right superior temporal gyrus) extending to parietal cortex (e.g., precuneus) were found in the PD patients with MCI relative to the healthy controls and PD patients without MCI.ROC analysis indicated that the area under the ROC curve (AUC) values in the frontal, temporal, and subcortical structures (e.g., insula and cerebellum) could differentiate the PD patients with MCI and without MCI and healthy controls. Furthermore, GMV of the right middle frontal gyrus and cortical thickness of the right superior temporal gyrus were correlated with neurocognitive dysfunctions (e.g., MOCA and MMSE) in PD patients with MCI.
conclusionThis study provided further evidence that PD with MCI was associated with structural alternations of brain. Morphometric analysis focusing on the cortical and subcortical regions could be biomarkers of cognitive impairments in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.